Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (81-90 of 418) with videos related to

Pageof 42
Sort By:
JAMA Ophthalmology|June 17, 2016
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic CancerMarissa L Weber, Michelle C Liang, Keith T Flaherty, et al.
Hematology/Oncology Clinics of North America|May 26, 2009
Drug targeting of oncogenic pathways in melanomaLeslie A Fecher, Ravi K Amaravadi, Lynn M Schuchter, et al.
Biochemical Society Transactions|August 12, 2014
One Hippo and many masters: differential regulation of the Hippo pathway in cancerDavid Romano, David Matallanas, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2003
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancyKeith T Flaherty, James P Stevenson, Stephen M Hahn, et al.
The Journal of Investigative Dermatology|October 14, 2011
p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibitionZhenyu Ji, Ching Ni Njauw, Michael Taylor, et al.
JCO Oncology Practice|January 25, 2021
REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology ClinicFarees Saqlain, Sophia Z Shalhout, Keith T Flaherty, et al.
Cancer Biology & Therapy|July 20, 2011
Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitorDavid T Dicker, Nadia Kahn, Keith T Flaherty, et al.
Journal of the American Academy of Dermatology|July 22, 2017
PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progressionStefan Kraft, Maria-Teresa Fernandez-Figueras, Nina A Richarz, et al.
Oncotarget|October 27, 2015
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanomaNeel M Fofaria, Dennie T Frederick, Ryan J Sullivan, et al.
Neurosurgical Focus|March 3, 2015
Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case seriesPamela S Jones, Daniel P Cahill, Priscilla K Brastianos, et al.
Pageof 42

Showing results (81-90 of 418) with videos related to

Sort By:
Pageof 42
JAMA Ophthalmology|June 17, 2016
Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic CancerMarissa L Weber, Michelle C Liang, Keith T Flaherty, et al.
Hematology/Oncology Clinics of North America|May 26, 2009
Drug targeting of oncogenic pathways in melanomaLeslie A Fecher, Ravi K Amaravadi, Lynn M Schuchter, et al.
Biochemical Society Transactions|August 12, 2014
One Hippo and many masters: differential regulation of the Hippo pathway in cancerDavid Romano, David Matallanas, Dennie T Frederick, et al.
Cancer Chemotherapy and Pharmacology|June 18, 2003
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancyKeith T Flaherty, James P Stevenson, Stephen M Hahn, et al.
The Journal of Investigative Dermatology|October 14, 2011
p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibitionZhenyu Ji, Ching Ni Njauw, Michael Taylor, et al.
JCO Oncology Practice|January 25, 2021
REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology ClinicFarees Saqlain, Sophia Z Shalhout, Keith T Flaherty, et al.
Cancer Biology & Therapy|July 20, 2011
Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitorDavid T Dicker, Nadia Kahn, Keith T Flaherty, et al.
Journal of the American Academy of Dermatology|July 22, 2017
PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progressionStefan Kraft, Maria-Teresa Fernandez-Figueras, Nina A Richarz, et al.
Oncotarget|October 27, 2015
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanomaNeel M Fofaria, Dennie T Frederick, Ryan J Sullivan, et al.
Neurosurgical Focus|March 3, 2015
Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case seriesPamela S Jones, Daniel P Cahill, Priscilla K Brastianos, et al.
Pageof 42